Jak-2 Mutation (Exon 12)

JAK2 Mutation (Exon 12)

What it is

The JAK2 Mutation (Exon 12) test detects specific genetic mutations in exon 12 of the JAK2 (Janus kinase 2) gene. While the more common JAK2 V617F mutation accounts for most cases of polycythemia vera (PV), exon 12 mutations are present in a smaller percentage of patients who also develop PV. Detecting these mutations helps identify the disease in patients who test negative for JAK2 V617F but still show clinical features of myeloproliferative disorders.

Uses

This test is primarily used to confirm or rule out polycythemia vera in patients with high red blood cell counts who tested negative for the JAK2 V617F mutation. It may also help distinguish PV from secondary causes of erythrocytosis (increased red blood cells) and support accurate disease classification and management.

Symptoms That May Lead to the Test

Doctors may recommend this test if you have persistent high hemoglobin or hematocrit levels, unexplained thickening of blood, or symptoms such as headaches, dizziness, blurred vision, itching after bathing, fatigue, blood clots, or an enlarged spleen. It is often ordered after a negative JAK2 V617F test when suspicion for PV remains high.

Abnormal Results

Positive for JAK2 Exon 12 Mutation: Strongly supports the diagnosis of polycythemia vera, even when JAK2 V617F is absent. This helps confirm a myeloproliferative neoplasm and guides treatment decisions.

Negative Result: Suggests no detectable exon 12 mutation. In such cases, other causes of erythrocytosis or additional molecular testing (such as CALR or MPL mutations) may be considered.

Risks

The test is performed on a routine blood sample, which carries minimal risks such as mild pain, bruising, or dizziness. In some cases, bone marrow studies may be needed for further evaluation, which carry slightly higher but manageable risks.